

FILING BY	"EXPRESS	MAIL"	UNDER	<b>37 CFR</b>	<u>1.10</u>

EV 457867 96405

December 6, 2004

Date of Deposit

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1625

RAY ET AL.

Examiner: Evelyn Huang

**APPLICATION NO: 10/621,670** 

FILED: JULY 17, 2003

FOR: NOVEL SALT AND POLYMORPHS OF DESLORATADINE

**HEMIFUMARATE** 

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

# FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

Date: December 6, 2004

John Thallemer
Attorney for Applicants
Reg. No. 34,940
862) 778-7945



## FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV45786796405 Express Mail Label Number

December 6, 2004 Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1625

RAY ET AL.

Examiner: Evelyn Huang

**APPLICATION NO: 10/621,670** 

FILED: JULY 17, 2003

FOR: NOVEL SALT AND POLYMORPHS OF DESLORATADINE

**HEMIFUMARATE** 

MS: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

Copy of this reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

John D. Thallemer

862) 778-7945

Attorney for Applicants Reg. No. 34,940

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

Date: December 6, 2004

**FORM PTO-1449** (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## RMATION DISCLOSURE CITATION

several sheets if necessary)

ATTY. DOCKET NO. RG/G-32603A APPLICATION NO. 10/621,670 **APPLICANT** RAY ET AL. **FILING DATE** JULY 17, 2003

Group 1625

	INFOR
PE	Use s
S ,	2004 55
DEC O B	DE COL
CATENT & TI	OF MEET
TATE TI	RAUE

# **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	АВ		•				
	AC	•					
	AD					. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	AE						
	AF		, -				
	AG						
	АН						
	Al						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	АМ	WO 02/42290 A1	5/30/02	PCT				
	AN							
	AO							
	AP							
	AQ							
		OTHER DOC	UMENTS	(Including Author, Title, Date, Pe	rtinent pages, E	tc.)		
	AR						-	
	AS							
	АТ							
EXAMINER		DATE CONSIDERED						

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.